Specific recommendations to improve the design and conduct of clinical trials

Area of Science:

• Biomedical Research
• Clinical Trial Design
• Translational Medicine

Background:

• Clinical trials frequently fail or show limited patient applicability due to restrictive criteria, short durations, and inadequate animal models.
• Current experimental animal models often fail to accurately simulate human disease, limiting their utility in predicting therapeutic outcomes.
• Reporting biases, such as preferential reporting of assigned therapy over actual use, further complicate trial interpretation.

Discussion:

• Suggests utilizing animal models that more accurately simulate human disease for determining investigational therapeutic dosing and outcomes.
• Proposes leveraging "big data" to identify and understand risk factors and confounding variables for improved clinical trial modeling.
• Advocates for accounting for and actively managing identified risk factors within trial models to enhance reliability.

Key Insights:

• Enhanced animal models are crucial for accurate preclinical testing and therapeutic development.
• Big data analytics can uncover complex risk factors, enabling more robust clinical trial designs.
• Proactive management of identified risks within trial protocols is essential for success.

Outlook:

• Future clinical trials could achieve higher success rates and greater patient applicability through refined preclinical modeling and data-driven risk management.
• This approach promises to bridge the gap between experimental findings and real-world clinical practice.
• Further research into sophisticated big data analytics and advanced animal disease models is warranted.